Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Karyopharm Therapeutics (KPTI) Gross Margin (2019 - 2025)

Karyopharm Therapeutics (KPTI) has disclosed Gross Margin for 5 consecutive years, with 95.64% as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Gross Margin fell 105.0% year-over-year to 95.64%, compared with a TTM value of 95.86% through Dec 2024, down 101.0%, and an annual FY2025 reading of 95.93%, up 6.0% over the prior year.
  • Gross Margin was 95.64% for Q4 2024 at Karyopharm Therapeutics, down from 96.65% in the prior quarter.
  • Across five years, Gross Margin topped out at 99.41% in Q4 2021 and bottomed at 94.23% in Q1 2024.
  • Average Gross Margin over 4 years is 96.77%, with a median of 96.76% recorded in 2023.
  • The sharpest move saw Gross Margin plummeted -498bps in 2022, then skyrocketed 226bps in 2023.
  • Year by year, Gross Margin stood at 99.41% in 2021, then dropped by -5bps to 94.44% in 2022, then rose by 2bps to 96.69% in 2023, then decreased by -1bps to 95.64% in 2024.
  • Business Quant data shows Gross Margin for KPTI at 95.64% in Q4 2024, 96.65% in Q3 2024, and 96.58% in Q2 2024.